Boston Scientific Corporation vs Harley-Davidson Inc — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while Harley-Davidson Inc trades at $25.23 (market cap $2.64B). The key difference: Boston Scientific Corporation is far larger — about 25.1× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.93% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | HOG | |
|---|---|---|
Market Cap | $66.37B | $2.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $31.03 |
52-Week Low | $42.63 | $17.19 |
Enterprise Value | $75.94B | $3.04B |
Dividend Yield | — | 2.93% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Harley-Davidson (HOG) trades at $25.39, up 0.99% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue from $5.8B in 2022 to $4.5B in 2025 and net income dropping to $339M, though valuation ratios remain attractive with P/E of 13.16 and P/B of 0.87. Recent news highlights production returning to US facilities and Q2 2026 earnings scheduled for July 23, 2026.
The outlook is cautiously optimistic with analyst consensus at Hold (65.71%) and price target of $23.40 below current price. Key opportunities include cost cuts and US production shift, while risks involve margin pressure and competitive threats. The stock faces headwinds from recent earnings misses but maintains dividend payments and institutional interest.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →